Overzicht Proefschriften
Tips in using the search/filter fieldsDisplaying 51-100 of 278 results.
| Titel | Promovendus | Promotor 1 | Promotor 2 | Copromotor 1 | Copromotor 2 | Universiteit | Promotiejaar | Trefwoorden |
|---|---|---|---|---|---|---|---|---|
| Neurovascular pharmacology of prospective antimigraine drugs | Chan K.Y., PhD | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2011 | Pharmacology; Migraine; Neurovascular pharmacology; | ||
| Neurovascular pharmacology of migraine: epigenetics and sex hormones | Labruijere S., PhD | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Pharmacology; Migraine; Epigenetics; Neurovascular pharmacology; | ||
| Challenges in using cardiovascular medications in Sub-Saharan Africa | Berhe D.F., PhD | Haaijer-Ruskamp F.M., prof. dr. | Taxis K., prof. dr. | Mol P.G.M., dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Pharmacology; Medication use; Cardiovascular disease; | |
| Cardiovascular molecular imaging | Haas H.J. de, PhD | Dierckx R.A.J.O., prof. dr. | Slart R.H.J.A., prof. dr. | Boersma H.H., dr. | Rijksuniversiteit Groningen (RUG) | 2018 | Pharmacology; Cardiovascular molecular imaging | |
| Aortic pathology and the role of the renin-angiotensin system | Molzer E., PhD | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2011 | Pharmacology; Cardiovascular disease; Renin-angiotensin system; | |||
| The alternative renin-angiotensin system: exploration of its therapeutic potential | Sevá Pessôa B., PhD | Danser A.H.J., prof. dr. | Roks A.J.M., dr. | Erasmus Universiteit Rotterdam (EUR) | 2015 | Pharmacology; Cardiovascular disease; Renin-angiotensin system; | ||
| Novel directions in therapy against age-related vascular disease | Wu H., PhD | Danser A.H.J., prof. dr. | Roks A.J.M., dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Pharmacology; Cardiovascular disease; | ||
| Advanced vascular imaging : technical and clinical applications in type 2 diabetes | Boer S.A. de, PhD | Kamphuisen T.P.W., prof. dr. | Slart R.H.J.A., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Pharmacology; advanced vascular imaging; Diabetes mellitus; | ||
| The therapeutic potential of Indoleamine 2.3-dioxygenase in kidney transplantation | Vavrinacova-Yaghi D., PhD | Henning R.H., prof. dr. | Sandovici M., dr. | Seelen M.A.J., dr. | Rijksuniversiteit Groningen (RUG) | 2014 | Pharmacology; kidney transplantation Indoleamine 2.3-dioxygenase | |
| Pharmacokinetics, pharmacodynamics and safety of different propofol formulations | Knibbe C.A.J., prof. dr. | Danhof M., prof. dr. | Aarts L.P.H.J., prof. dr. | Kuks P.F.M., dr. | Universiteit Leiden (UL) | 2002 | Pharmacokinetics; Pharmacodynamics; Propofol; | |
| Don't be afraid! Population PK-PD modeling as the basis for individualized dosing in children and critically ill | Peeters M.Y.M., dr. | Danhof M., prof. dr. | Tibboel D., prof. dr. | Knibbe C.A.J., prof. dr. | Universiteit Leiden (UL) | 2007 | Pharmacokinetics; Pharmacodynamics; Children; Sedation; Critically ill; Intensive care; NONMEM; Propofol; Midazolam; | |
| Pharmacokinetic insights in individual drug response; a model-based approach to quantify individual exposure-response relationships in type 2 diabetes | Koomen J.V. | Lambers Heerspink H.J., prof. dr. | Mol P.G.M., dr. | Stevens J., Dr. | Rijksuniversiteit Groningen (RUG) | 2021 | Pharmacokinetic insights in individual drug response; a model-based approach to quantify individual exposure-response relationships in type 2 diabetes | |
| Challenges and opportunities in pharmacogenomics: studies in cardiovascular disease and asthma | Leusink M., PhD | Boer A. de, prof. dr. | Bakker P.I.W. de, prof. dr. | Maitland-van der Zee A.H., prof. dr. | Onland-Moret N.C., dr. | Universiteit Utrecht (UU) | 2015 | Pharmacogenomics; Cardiovascular disease; Asthma; Genomics; Genetics; Pharmacology; Statins; Inhaled corticosteroids; Cholesterol; |
| Use of real-world evidence in pharmaeconomic analysis | Huang Y. | Haaijer-Ruskamp F.M., prof. dr. | Postma M.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2019 | Pharmacogenomics; | ||
| Translating pharmacogenetics to primary care | Swen J.J., PhD | Guchelaar H.J., prof. dr. | Assendelft W.J.J., prof. dr. | Wessels J.A.M., dr. | Universiteit Leiden (UL) | 2011 | Pharmacogenetics; Primary care; | |
| Treatment optimization of fluoropyrimidines as single agent and in combination therapy | Deenen M.J., PhD | Schellens J.H.M., prof. dr. | Beijnen J.H., prof. dr. | Cats A., dr. | Universiteit Utrecht (UU) | 2011 | Pharmacogenetics; Fluoropyrimidines; Capecitabine; 5-fluorouracil; Dihydropyrimidine dehydrogenase; Dihydropyrimidine dehydrogenase; DPD-deficiency; | |
| Pharmacogenetics of antihypertensive drug treatment | Wieren-de Wijer B.M.A. van, dr. | Boer A. de, prof. dr. | Stricker B.H.C., prof. dr. | Klungel O.H., prof. dr. | Maitland-van der Zee A.H., prof. dr. | Universiteit Utrecht (UU) | 2009 | Pharmacogenetics; Antihypertensive drugs; Study design; Observational studies; UIPS; |
| Improving acceptance of pharmacogenetic testing in clinical care | Bank P.C.D., PhD PharmD | Guchelaar H.J., prof. dr. | Swen J.J., PhD | Universiteit Leiden (UL) | 2018 | Pharmacogenetics, pharmacogenomics, primary care, Clinical-decision-support, drug-safety | ||
| Continuity of pharmaceutical care for psychiatric patients | Abdullah-Koolmees H., PhD | Egberts A.C.G., prof. dr. | Heerdink E.R., dr. | Gardarsdottir H., dr. | Universiteit Utrecht (UU) | 2015 | Pharmaceutical care; Medication; Hospitalization; Somatic; Discharge; Discontinuation; Rehospitalization; Rehospitalization prediction; | |
| Exploring strategies to individualize treatment with aminoglycosides and co-trimoxazole for MDR Tuberculosis | Dijkstra J.A., PhD | Werf T.S. van der, prof. dr. | Kosterink J.G.W., prof. dr. | Alffenaar J.W.C., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Personalized medicine; Tuberculosis; | |
| Paving ways for personalizing drug therapy during pregnancy | Daud N.A.A., PhD | Wilffert B, prof. dr. | Kammen-Bergman J.E.H. van, dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Personalized medicine; Drug therapy; Pregnancy; | ||
| The Clinical Pharmacology of performance enhancement and doping detection in sports | Heuberger J., dr. | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Rotmans J.I., dr. | Universiteit Leiden (UL) | 2019 | Performance enhancement and doping detection in sports | |
| Clinical decision support in community pharmacy | Heringa M., PhD | Bouma H.R., PhD | Smet P.A.G.M. de, prof. dr. | Floor-Schreudering A., PhD PharmD | Universiteit Utrecht (UU) | 2017 | Patient safety; Clinical decision support system; Community pharmacy; Drug therapy; | |
| The use of a battery of evoked pain models in early phase drug development | Okkerse P. | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Universiteit Leiden (UL) | 2018 | Pain Human pain models Analgesics Clinical pharmacology Pharmacodynamics Drug Development | ||
| Novel approach to characterize developmental changes in pharmacokinetics across the human lifespan: application to the prediction of clearance in children | Wang C., PhD | Knibbe C.A.J., prof. dr. | Danhof M., prof. dr. | Tibboel D., prof. dr. | Universiteit Leiden (UL) | 2013 | Paediatrics; Scaling clearance; Population PK; Morphine; Morphine; Paracetamol; Bodyweight-dependent exponent model; Pharmacometrics; Allometric scaling; NONMEM; Pharmacokinetics; | |
| Towards a system-based pharmacology approach to predict developmental changes in renal drug clearance in children | De Cock R.F.W., PhD | Knibbe C.A.J., prof. dr. | Danhof M., prof. dr. | Allegaert K., prof. dr. | Universiteit Leiden (UL) | 2014 | Paediatrics; Population PK; Aminoglycosides; Propylene glycol; GFR; Renal function; Antibiotics; Glomerular filtration; Developmental changes; Pharmacokinetics; Newborns; | |
| Size does matter : drug glucuronidation in children | Krekels E.H.J., PhD | Knibbe C.A.J., prof. dr. | Tibboel D., prof. dr. | Universiteit Leiden (UL) | 2012 | Paediatrics; Morphine; Population PK; System-specific covariate modelling; Model validation; Glucuronidation; Ontogeny; Pharmacokinetics; UGT2B7; Zidovudine; | ||
| Maturation of cytochrome P450 3A mediated drug metabolism : towards individualized dosing in children | Ince I., PhD | Tibboel D., prof. dr. | Knibbe C.A.J., prof. dr. | Wildt S.N. de, prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2013 | Paediatrics; Midazolam; CYP3A; Population PK; Maturation; Metabolism; | |
| Child friendly medicines : availability, pharmaceutical design, usability and patient outcomes | Riet-Nales D.A. van, PhD | Schobben A.F.A.M., prof. dr. | Egberts A.C.G., prof. dr. | Rademaker C.M.A., dr. | Universiteit Utrecht (UU) | 2014 | Paediatrics; Drug compounding; Consumer satisfaction; Formulation; Mini tablet; Splitter; Usability; EMA; | |
| Minimally invasive methodology for pharmacological research involving children | Klein R.H., PhD | Cohen A.F., prof. dr. | Burggraaf J., prof. dr. | Sukhai R.N., dr. | Universiteit Leiden (UL) | 2013 | Paediatrics; Clinical pharmacology; ADHD; Pharmacokinetics; Growth hormone deficiency; Pharmacodynamics; Point of care technology; | |
| How to scale clearance from adults to children for drugs undergoing hepatic metabolism? Insights from advanced PBPK modelling and simulation | Calvier E.A.M., PhD | Knibbe C.A.J., prof. dr. | Tibboel D., prof. dr. | Krekels E.H.J., PhD | Universiteit Leiden (UL) | 2018 | Paediatrics; Clearance; Allometric scaling; Hepatic metabolism; Physiologically based pharmacokinetics; Pharmacokinetics; Optimal design; Scaling clearance; | |
| Individualization of drug exposure in pediatric hematopoietic stem cell transplantation | Bartelink I.H., PhD | Egberts A.C.G., prof. dr. | Danhof M., prof. dr. | Boelens J.J., dr. | Knibbe C.A.J., prof. dr. | Universiteit Utrecht (UU) | 2012 | Paediatrics; Busulfan; Hematopoietic stem cell transplantation; |
| Adherence to antiretroviral combination therapy in children : what a difference half a day makes... | Piana C., PhD | Danhof M., prof. dr. | Della Pasqua O.E., dr. | Universiteit Leiden (UL) | 2013 | Paediatrics; Antiretroviral combination therapy; Compliance; Antiretroviral drugs; Paediatric populations; Drug combinations; Model-based; Covariate analysis; Predictive pharmacokinetic models; Clinical trial simulations; Adherence; Forgiveness of non-adherence; | ||
| Priority medicines for children : exploring age-appropriate medicines and antibiotic use in children | Ivanovska V., PhD | Leufkens H.G.M., prof. dr. | Mantel-Teeuwisse A.K., dr. | Dijk C.E.M.J. van, dr. ir. | Universiteit Utrecht (UU) | 2017 | Paediatric pharmacotherapy; Paediatric drug development; Priority setting; Age-appropriate formulations; Antibiotic use; Children; | |
| Osteoarthritis : association with diabetes mellitus, and treatment-related outcomes | Nielen J.T.H., PhD | Boonen A.E.R.C.H., prof. dr. | Dagnelie P.C., prof. dr. | Vries F. de, prof. dr. | Bemt B.J.F. van den, dr. | Universiteit Maastricht (UM) | 2018 | Osteoarthritis; Diabetes mellitus; Hip; Knee; Treatment outcomes; |
| Challenges in the clinical development of orphan drugs | Kreeftmeijer-Vegter A.R., PhD | Boer A. de, prof. dr. | Vries P.J. de, dr. | Universiteit Utrecht (UU) | 2015 | Orphan drugs; Clinical development; Paediatric formulation; Pharmacokinetics; Efficacy; Safety; Regulatory; | ||
| Pharmacological approaches to optimize TB treatment | Zuur M.A. | Alffenaar J.W.C., prof. dr. | Werf T.S. van der, prof. dr. | Rijksuniversiteit Groningen (RUG) | 2018 | Optimize; Tuberculosis; Treatment; | ||
| Exploring optimal pharmacotherapy after bariatic surgery: where two worlds meet | Yska J.P., PhD | Roon E.N. van, prof. dr. | Wilffert B, prof. dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Optimal pharmacotherapy; Bariatric surgery; | ||
| Anti sense and sensibility : renal and skin effects of (antisense) oligonucleotides | Meer, van L., Dr. | Cohen A.F., prof. dr. | Burggraaf J., prof. dr. | Moerland M., dr. | Universiteit Leiden (UL) | 2017 | Oligonucleotide Antisense Type 2 diabetes mellitus Clinical trial Phase2study | |
| Performence of statistical methods to control for unmeasured confounding in pharmacoepidemiology : focus on instrumental variable analysis | Uddin M.J., MD PhD | Boer A. de, prof. dr. | Roes K.B.C., prof. dr. | Groenwold R.H.H., dr. | Klungel O.H., prof. dr. | Universiteit Utrecht (UU) | 2014 | Observational studies; Pharmacoepidemiology; Confounding; Statistical methods; Instrumental variables; SCCS; PERR; |
| Shaping the pharmacokinetic landscape for renally cleared antibiotics in obesity: Studies in adults, adolescents and children | Smit C., PhD | Knibbe C.A.J., prof. dr. | Dongen H.P.A. van, dr. | Brüggemann R.J.M., PhD | Universiteit Leiden (UL) | 2020 | Obesity; Morbid obesity; Pharmacokinetics; Obese children; Obese adolescents; Gentamicin; Tobramycin; Aminoglycosides; Vancomycin; Renal clearance; Population pharmacokinetics; Antibiotics; Individualized dosing; Adolescents; | |
| Diagnosis and treatment of obese children with insulin resistance | Aa M.P. van der, PhD | Knibbe C.A.J., prof. dr. | Boer A. de, prof. dr. | Vorst M.M.J. van der, dr. | Universiteit Leiden (UL) | 2016 | Obesity; Children; Insulin resistance; Metformin; | |
| Non-invasive monitoring of pharmacokinetics and pharmacodynamics for pharmacological drug profiling in children and adolescents | Schrier L., PhD | Cohen A.F., prof. dr. | Gerven J.M.A. van, prof. dr. | Sukhai R.N., dr. | Universiteit Leiden (UL) | 2015 | Non-invasive monitoring; Pharmacokinetics; Pharmacodynamics; Pharmacological drug profiling; Children; Adolescents; | |
| Challenging the cholinergic system: ageing, cognition & inflammation | Alvarez-Jimenez R., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Universiteit Leiden (UL) | 2017 | Neuropsychopharmacology Clinical Pharmacology Trials Cognition Dementia Cholinergis system Drug development | |
| Measuring pharmacodynamics in early clinical drug studies in multiple sclerosis | Kanhai K.M.S | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Universiteit Leiden (UL) | 2019 | Multiple sclerosis Drug development Biomarkers Remyelination | ||
| An orchestra in need of a conductor challenges and opportunities in multi-infusion therapy | Doesburg F | Touw D.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2021 | multi-infusion therapy | |||
| Pain still hurts : pain assessment and pain management in intensive care patients | Ahlers S.J.G.M., PhD | Tibboel D., prof. dr. | Knibbe C.A.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2012 | Morphine; Remifentanil; Pain; Immune reconstitution; Intensive care; Critically ill; Analgesia; Anesthesiology; Pain assessment; Pain management; | ||
| The impact of obesity on the pharmacokinetics of drugs in adolescents and adults | Rongen A. van, PhD | Knibbe C.A.J., prof. dr. | Anker J.N. van den, prof. dr. | Dongen H.P.A. van, dr. | Ramshorst B. van, dr. | Universiteit Leiden (UL) | 2016 | Morbid obesity; Pharmacokinetics; Obese adolescents; Midazolam; Acetaminophen; Medication use; Medication use; Metformin; |
| Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery | Brill M.J.E., PhD | Knibbe C.A.J., prof. dr. | Dongen H.P.A. van, dr. | Ramshorst B. van, dr. | Universiteit Leiden (UL) | 2016 | Morbid obesity; Cefazolin; Midazolam; Bariatric surgery; Microdialysis; P53-deficient ovarian cancer; PK-PD modelling; | |
| Suurs F | Vries E.G.E. de, prof. dr. | Lub-de Hooge M.N., dr. | Rijksuniversiteit Groningen (RUG) | 2021 | Molecular imaging of immunotherapy biodistribution and the tumor immune environment |